Mark A. Schlossberg net worth and biography

Mark Schlossberg Biography and Net Worth

Mark joined us as Senior Vice President, Legal and General Counsel in January 2019.

Prior to joining Cytokinetics, Mark served as Senior Vice President, General Counsel and Secretary at Impax Laboratories, a position he held since May 2011. Previously, he served as Associate General Counsel at Amgen from 2004 until 2011, and in positions of increasing responsibility in the legal departments at Medtronic, Diageo and RJR Nabisco.

Mark graduated with a B.S. in Business Administration/Finance from the University of Southern California, and a J.D. from Emory University School of Law.

Mark and his wife Pam spend their spare time with their family, including their two grandchildren. Mark is a Warriors, Red Sox and NY Giants fan (due to the fact that he grew up in the suburban area of NYC).

What is Mark A. Schlossberg's net worth?: The estimated net worth of Mark A. Schlossberg is at least $2.39 million as of August 21st, 2020. Mr. Schlossberg owns 40,000 shares of Cytokinetics stock worth more than $2,390,400 as of May 16th. This net worth evaluation does not reflect any other assets that Mr. Schlossberg may own. Learn More about Mark A. Schlossberg's net worth.
How do I contact Mark A. Schlossberg?: The corporate mailing address for Mr. Schlossberg and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Mark A. Schlossberg's contact information.
Has Mark A. Schlossberg been buying or selling shares of Cytokinetics?: Mark A. Schlossberg has not been actively trading shares of Cytokinetics during the last quarter. Most recently, Mark A. Schlossberg sold 25,196 shares of the business's stock in a transaction on Tuesday, March 15th. The shares were sold at an average price of $33.96, for a transaction totalling $855,656.16. Learn More on Mark A. Schlossberg's trading history.
Who are Cytokinetics' active insiders?: Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (CEO), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?: During the last year, insiders at the biopharmaceutical company sold shares 32 times. They sold a total of 380,121 shares worth more than $21,153,114.78. The most recent insider tranaction occured on May, 7th when EVP Fady Ibraham Malik sold 15,547 shares worth more than $1,012,265.17. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.
Information on this page was last updated on 5/7/2024.

Mark A. Schlossberg Insider Trading History at Cytokinetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2022	Sell	25,196	$33.96	$855,656.16
10/19/2021	Sell	19,979	$35.74	$714,049.46
8/21/2020	Sell	10,000	$25.00	$250,000.00	40,000
7/29/2020	Sell	10,000	$23.07	$230,700.00	40,000

Mark A. Schlossberg Buying and Selling Activity at Cytokinetics

Cytokinetics Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $59.76

$59.50

$61.04

50 Day Range

MA: $66.95

$57.89

$75.05

2 Week Range

Now: $59.76

$25.98

$110.25

Volume

228,447 shs

Average Volume

2,686,449 shs

Market Capitalization

$6.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

This is the best new way to score with AI

From Weiss Ratings | Ad

If you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open.

Click now for the best way into the newest AI projects